BioLineRx is trading 6.07% up at $3.02, extending its rebound amid recent biotech strength following positive clinical-trial news across the sector.
- It has rebounded from the $2.76 close on August 20, 2026.
- No new company-specific announcement clearly explains the August 24 move; the rally is not directly confirmed as company-specific.
- Reported volume is 1.04K, versus a 21.97K three-month average; broader indexes are mixed.